How to deal with the consent of adults with cognitive impairment involved in European geriatric living labs?

Guillaume Sacco 1,2,3*, Frédéric Noublanche 1,2, Frédéric Blazek 4, Catherine Hue 4, Loïc Carballido 4, Marine Asfar 1, Philippe Allain 2 and Cédric Annweiler 1,2,5*

Abstract

Background: Living labs are realistic environments designed to create links between technology developers and end-users (i.e. mostly older adults). Research in LLH (Living labs in health) covers a wide range of studies from non-interventional studies to CT (clinical trials) and should involve patients with neurocognitive disorders. However, the ethical issues raised by the design, development, and implementation of research and development projects in LLH have been the subject of only little interest thus far.

Objective: Our aim was to determine a pragmatic, ethical and regulatory correct approach to seek the informed consent of patients with neurocognitive disorders according to the different types of studies carried out in European LLH, with a focus on the French context.

Methods: A narrative review of regulatory texts and clinical articles was conducted, and a pragmatic procedure to determine the decision-making capacity of older adults in LLH was proposed.

Results: Individuals must be adequately informed and freely agree to participate in CT. The capacity to consent should be assessed in CT including cognitively impaired older adults. We propose the following steps: first to assess for delirium using the 4 ‘A’s Test (4AT) or the 3-min Diagnostic interview for Confusion Assessment Method (3D-CAM), second to search for medical history of major neurocognitive disorder, and third to assess the decision capacity using the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC).

Conclusions: Including individuals with neurocognitive disorders in research implies using an efficient and pragmatic strategy to inform participants and obtain their consent. The tool we offer here may be useful in the routine operation of LLH but can also be extended to all CT with this population.

Keywords: Living lab, Geriatrics, Older adults, Consent, Ethics

* Correspondence: sacco.g@chu-nice.fr; CeAnnweiler@chu-angers.fr; cedric.annweiler@chu-angers.fr

1 Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

The increases in life expectancy and in the proportion of very old, polymorbid, frail and disabled adults generate new needs. Today it proves urgent to radically innovate and offer new services or divert new uses to meet these needs. The challenge is to innovate efficiently, and in line with the real needs of users, in their diversity. Living labs in health (LLH) are precisely thought to fill the gap between the solutions proposed by developers of new uses or technologies and the real needs of users with specific health issues. Living labs are realistic environments designed to create links between technology developers and end-users. Living labs enable end-users to communicate their needs and expectations directly to technology developers (co-design), and to participate in prototype testing (codevelopment) [1, 2]. LLH appear particularly appropriate to vulnerable groups, including older adults with diseases and/or loss of function [3].

Research in LLH covers a wide range of studies from non-interventional studies to clinical trials. However, the ethical issues raised by the design, development, and implementation of research and development projects in LLH have been the subject of only little interest thus far [4, 5]. This question is not, however, so simple. For instance, in our ALLEGRO LLH, in which real sick older patients are hospitalized to allow them participating to tests in real conditions [6], a number of patients with neurocognitive disorders are still excluded from the LLH process because of the lack of standardized procedure to determine their incapacity to consent. This is all the less acceptable as these exclusions go against the objective of ALLEGRO, which was precisely to include in the process of innovation all real-life older patients. Therefore, older adults with neurocognitive disorders should be integrated in research projects, and are able to participate [7]. This is also in line with guidance related to work with older and/or disabled adults [8–16]. In this context, particular attention should therefore be paid to the ethical issues raised by cognitively-impaired older adults [5, 7, 17]. Questioning the need for including such people in studies should be thought during the design of the study and validating by ethics committees. Our aim here was to determine a pragmatic, ethical and regulatory correct approach to seek the informed consent of patients with neurocognitive disorders according to the different types of studies carried out in LLH.

Regulatory reminders for non-interventional research

In France, non-interventional research must be divided in two categories. On the one hand, research implying human being (i.e. category 3 of the article L1121–1 from the French public health code), on the other hand research on data.

Research on data is not considered as a research implying human being. It concerns only observational researches on health data collected in usual health care and researches without collection of health data (e.g. questionnaires with healthcare professionals or satisfaction surveys). Regulation concerning research on data is provided by the regulation (EU) 679/2016 on general data protection (GDPR) [18]. This regulation explains that personal data shall be processed lawfully i.e., the individual is expected to give consent to the processing of personal data for one or more specific purposes (article 6), fairly, and in a transparent manner in relation to the data subject (article 5). Moreover, it is necessary to assess whether the consent is freely given (article 7). Thus, even if not clearly defined as "informed", the capacity to consent remains at the center of the decisional process. Nevertheless, for data concerning research (Article 21.6 of the GDPR) the person “shall have the right to object to processing of personal data concerning him or her”. Moreover, article 9.4 state that “member States may maintain or introduce further conditions, including limitations, with regard to the processing of genetic data, biometric data or data concerning health”. In France, according to the article 73 from the law n°78–17 of January 6th. 1978 (law informatics and freedoms), patients could have only general information regarding the research project and not objecting to processing their personal data.

The Oviedo convention [19, 20] frame researches implying human being in non-interventional studies as this convention is applying for all researches in biology and health. It concerns studies without specific risks, constraints or modification of usual care for the patient (i.e. observational prospective studies). For researches implying human being in non-interventional studies, the patient should be informed regarding the research. Expression of consent differ across European countries from the non-express opposition in France (article L1122.1.1 from the French public health code), to informed consent (e.g. in Belgium).

Regulatory reminders for clinical trials

As detailed by Brugère and Gzil [21], several regulatory texts govern the informed consent in clinical trials. “Informed consent” is the voluntary agreement of an individual, or the legally acceptable representative, who has the legal capacity to give consent, and who exercises free power of choice, without undue inducement or any other form of constraint or coercion to participate in research [22]. The individual must have sufficient knowledge and understanding of the nature of the proposed research, the anticipated risks and potential benefits, and the requirements of the research to be able to make an informed decision. The main regulatory texts used in
Europe are the declaration of Helsinki from the world medical association [23]; the Oviedo convention [19, 20], the guideline for good clinical practice E6(R2) from the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use [24]; the regulation (EU) 536/2014 on clinical trials on medicinal products for human use [25], and the regulation (EU) 679/2016 on general data protection [18] from the European Parliament. In France, clinical trials are divided in two categories (article L1121–1 French health public code); a) category 1 are interventional researches including intervention on human being which is no related to usual care, b) category 2 are interventional researches with only low risks and constraints.

For clinical trials including cognitively healthy older adults, the guideline is as follows: i) the individual is adequately informed (article L1122–1 French health public code); ii) the individual freely agrees to participate (in the French law, written consent is mandatory for category 1 clinical trials contrarily to category 2 clinical trial, were consent could be unwritten; article L1122-1-1 health public code); iii) the consent is regularly repeated.

For clinical trials including cognitively-impaired older adults (article L1122–2 French health public code), it must first be determined whether the clinical trial relates directly to a medical condition from which the individual suffers, and whether the research cannot instead be conducted with individuals capable of providing informed consent. The investigator must seek i) informed consent of the legally acceptable representative, and ii) the assent of the patient whenever possible [23]. “Assent” is a term used to express willingness to participate in research by persons who are not able to give informed consent but who are able to understand the proposed research in general, its expected risks and possible benefits, and the activities expected of them as participants. Assent by itself is not enough and must be supplemented with informed consent of the legally acceptable representative. To be as close as possible to the will of the individual losing autonomy, this substituted decision refers to the concept of authenticity [26]. Unlike autonomy, which is ability to provide informed consent, the concept of authenticity is based on the individual’s values (hopes, beliefs, commitments and relationships), and allows substituted judgment, in which the surrogate attempts to decide what the patient ‘would have chosen’. Thus, a decision can be authentic even when made by a surrogate, because authenticity does not require intact capacity for self-determination, only that the decision conforms to the individual’s values [26].

Thus, whether for non-interventional or interventional studies, the whole question is to assess the decision-making capacity of potential participants with neurocognitive disorders in order to determine whether they are able to consent by themselves.

Proposal of a pragmatic procedure to screen for decision-making incapacity of older adults in LLH

The procedure we propose here is based on our experience as clinicians, has been designed to be routinely feasible, and is consistent with regulatory texts (Fig. 1).

First, we propose that individuals should be screened for delirium, as up to 30% of older patients over 80 years suffer from delirium in geriatric acute care units [27], and because more than 60% of delirium are undiagnosed [28] (Fig. 1). The screening for delirium should be both accurate and feasible i.e., with a short administration time and a high negative predictive value. Several tools are proposed [29, 30], including the confusion assessment method (CAM) [31–33], the 3-min Diagnostic interview for Confusion Assessment Method (3D-CAM) [34] or the 4 ‘A’s Test (4AT) [35, 36]. The advantage of the 4AT is that it does not require any training period and its administration takes less than 2 min [35]. Moreover, it exhibits a high negative predictive value, between 96% for the English version [36] and 98% for the French version [37].

The issue most frequently met in ALLEGRO is the presence of major neurocognitive disorders, with at least 40% of patients in geriatric acute care units suffering from major cognitive disorders [38]. Thus, as illustrated in Fig. 1, the second step should be to look for the medical history of major neurocognitive disorders.

Third, the capacity to consent should be assessed according to the medical history of major neurocognitive disorders and to the diagnosis of delirium.

Of note, the decision-making capacity varies among patients with neurocognitive disorders [39], and 30% of cognitively-impaired patients are actually deemed capable to consent [40]. Several tools are proposed to assess the capability to consent [41, 42]. The MacArthur competence assessment tool for clinical research (MacCAT-CR) [43] is the most cited one but it requires 15–20 min of administration, and also a substantial training to certify the administration and interpretation. In contrast, the University of California Brief Assessment of Capacity to Consent (UBACC) [44] requires less than 5 min of administration. A French version has been validated with older adults suffering from neurocognitive disorders; with a sensibility and a specificity of 100% using a cut-off ≤12/20 [45].

Finally, as discussed above, consent should be sought either from the individual when the decision-making capacity is preserved or from the legal representative with the assent of the individual when the decision-making capacity is altered (Fig. 1). If divergent opinions occur between the legally acceptable representatives of a patient considered as having altered decision-making capacity, we are recommending stopping the research process and to continue the standard cares as they are the best-known cares.
Making information accessible and understandable to individuals with neurocognitive disorders

Educational psychology literature suggests that effective learning can be improved by multimodal presentation [46]. Such multimodal approach has driven Dewing to help patients better understanding studies information [47]. In particular, video has been used to improve informed consent in cognitively healthy patients [48–51]. This media seems to improve understanding also in participants with low education [52] and psychiatric disorders [53]. However, the most recent systematic review reports that the benefit of audio-visual support remains unclear to enhance informed consent [54]. In any case, it is imperative to ensure that the individual and relatives have understood the issue, the benefits and the risks of the studies that are offered to them in the LLH. Novel approaches using mHealth and interactive informed consent could be an attractive option in the near future [55].

Ensuring over time that the participant remains consenting to the study

When undertaking research with individuals with neurocognitive disorders, the literature introduces the concepts of “process consent” [47] or “rolling consent” [56, 57] to ensure willing participation. These include i) the necessity to repeat information on an iterative basis (i.e., not only when requested) and asking for consent (or assent) during the various stages of the research development; ii) listening to the content and nuances of the speech and continuously assessing whether participation is voluntary; iii) communicating the possibility of opting out or withdrawing from research at any given stage [56]. Thus, rolling informed consent results in a continuous consideration of the choices made by the vulnerable person [56].

Conclusions

The principle of LLH like ALLEGRO is to connect technology developers with all users of the geriatric hospital
environment, including patients with neurocognitive disorders. This implies using an efficient and pragmatic strategy to inform participants and obtain their consent, or their assent and the consent of their legally acceptable representative if applicable. The tool we offer here may be useful in the routine operation of LLH but can also be extended to all clinical trials in general. Further studies are needed to ensure the feasibility of this algorithm.

Abbreviations
3D-CAM: 3-min Diagnostic interview for Confusion Assessment Method; 4AT: 4 ‘A’S Test; ALLEGRO: Angers Living Lab En Gérontièr eHopitalière; CAM: Confusion Assessment Method; GDPR: General Data Protection Regulation; LLH: Living Labs for Health; MacCAT-CR: MacArthur Competence Assessment Tool for Clinical Research; UBACC: University of California Brief Assessment of Capacity to Consent

Acknowledgements
The authors have listed everyone who contributed significantly to the work in the Acknowledgments section. Permission has been obtained from all persons named in the Acknowledgments section.

Melinda Beaudenon, MSc, Jennifer Gautier, MSc, Anne Renaudin and Romain Simon MSc, from Research Center on Autonomy and Longevity, University Hospital of Angers, France, for daily assistance. There was no compensation for this contribution.

Authors’ contributions
CA has full access to all of the data in the study, takes responsibility for the data, the analyses and interpretation and has the right to publish any and all data, separate and apart from the attitudes of the sponsors. All authors have read and approved the manuscript. Study concept and design (GS and CA). Acquisition of data (GS). Analysis and interpretation of data (GS, FR, and CA). Drafting of the manuscript (GS, and CA). Critical revision of the manuscript for important intellectual content (FN, FB, CH, LC, MA and PA). Obtained funding (CA). Statistical expertise (not applicable). Administrative, technical, or material support (CA). Study supervision (CA).

Funding
GS is supported by a postdoctoral grant from Research Center on Autonomy and Longevity, University Hospital of Angers, France (2019–2020). FN is supported by a doctoral fellowship grant from Angers Loire Métropole (2018–2021). CA’s program ALLEGRO is supported in part by a grant “Plus de Vie 2017” from “Fondation Hôpitaux de Paris Hôpitaux de France”. The sponsors had no role in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

Availability of data and materials
There are no linked research data sets for this paper.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
All authors state that they have no conflicts of interest with this paper. The authors have no relevant personal financial interest in this manuscript.

Author details
1Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France. 2Univ Angers, Université de Nantes, LPLF, SFR CONFLUENCES, F-49000, Angers, France. 3Université Côte d’Azur, CoBTeck, Nice, France. 4Direction, University Hospital, Angers, France. 5Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.

Received: 15 July 2020 Accepted: 25 May 2021
Published online: 16 June 2021

References
1. Annweiler C, Noublanche F, Jaglin-Grimonprez C, Bubien Y. Built environments for frail older adults: the now and next. Maturitas. 2018;116:137–8. https://doi.org/10.1016/j.maturitas.2018.05.006.
2. Noublanche F, Jaglin-Grimonprez C, Laignel L, Sacco G, Allain P, Annweiler C. Adapting Gerontechnological development to hospitalised frail older people: implementation of the ALLEGRO hospital-based geriatric living lab. J Am Med Dir Assoc. 2020;21(4):350–4. https://doi.org/10.1016/j.jamda.2020.01.001.
3. Kim J, Kim YL, Jang H, Cho M, Lee M, Kim J, et al. Living labs for health: an integrative literature review. Eur J Pub Health. 2020;30(1):55–63. https://doi.org/10.1093/europub/ckz105.
4. Habibpour A, Stahlbrotz A, Georges A, Bergwall-Kireborn B. Drop-out in living lab field test: analyzing consequences and some recommendations. Twenty-Sixth European Conference on Information Systems (ECIS2018), Portsmouth, UK, 2018. Presented at the 26th European Conference on Information Systems (ECIS2018), Portsmouth, UK, 23–28 June 2018. Retrieved from http://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-69367.
5. Sainz F. Emerging ethical issues in living labs. Romon Llull J Appl Eth. 2012;3(3):47. https://doi.org/10.4103/2013-8393.107298.
6. Noublanche F, Jaglin-Grimonprez C, Sacco G, Lefolle N, Allain P, Annweiler C, et al. The development of gerontechnology for hospitalized frail elderly people: the ALLEGRO hospital-based geriatric living lab. Maturitas. 2019;125:17–9. https://doi.org/10.1016/j.maturitas.2019.04.002.
7. Pino M, Benveniste S, Kerherve H, Legouerveur G, Cristancho-Lacroix V. Contribution of the Living Lab approach to the development, assessment and provision of assistive technologies for supporting older adults with cognitive disorders. Stud Inform Univ. 2013;11:54–62.
8. Gallati TC, Moody L, Saunders J, Ward G, Woodley J. Stakeholder requirements for an ethical framework to sustain multiple research projects in an emerging living lab involving older adults. J Empir Res Hum Res Ethics. 2019;15:111–27.
9. Finlay L. Reflexivity: an essential component for all research? Brit J Occup Ther. 1998;61:53–6.
10. Gill M, Gilmam L. Ethics, reflexivity, and “ethically important moments” in research. Qualitative Inquiry. 2004;10:261–80.
11. Vines J, McNaney R, Holdens A, Polakow I, Wright P, Olivier P. Our year with the glass: expectations, letdowns and ethical dilemmas of technology trials with vulnerable people. Interact Comput. 2017;29(1):127–44. https://doi.org/10.1016/j.ic.2017.04.001.
12. Mackin ML, Henri K, Bergen-Jackson K, Fine P, Forcucci C, Sanders S. Research participation by older adults at end of life: barriers and solutions. Res Gerontol Nurs. 2009;2(3):162–71. https://doi.org/10.1097/01.rrn.0000369611.62273.8d.
13. McGuire J. Ethical considerations when working with older adults in psychology. Ethics Behav. 2009;19(2):112–28. https://doi.org/10.1080/10508420902772702.
14. Ramcharan P, Cutcliffe JR. Judging the ethics of qualitative research: considering the “ethics as process” model. Health Soc Care Commun. 2001; 9(6):358–66. https://doi.org/10.1002/hsc.416.
15. Tinker A. Older people and ethics. Austr J Ageing. 2003;22(4):206–10. https://doi.org/10.1111/1741-6612.2003.tb00499.x.
16. Waycott J, Morgans A, Pedell S, Ozanne E, Vetere F, Kulik L, et al. Ethics in a sociotechnical intervention with socially isolated older adults. Qual Health Res. 2015;25(11):1518–28. https://doi.org/10.1177/1049732315570136.
17. Beattie BL. Consent in Alzheimer’s disease research: risk/benefit factors. Can J Neurol Sci. 2007;34(5):527–31. https://doi.org/10.1017/ S0317167107000557.
18. The European Parliament, The Council of the European Union. Regulation on the protection of natural persons with regard to the processing of personal data and on the free movement of such data. 2016. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0679&from=EN (Accessed 17 Dec 2019).
19. Council of Europe. Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research. 2005.
20. Council of Europe. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine. Treaty No. 164, 1997.
21. Brugère S, Giff F. Pour des technologies au service des capacités et du bien commun. Paris: France: Filière Silver Economie; 2019.

22. Levine RJ. Ethics and regulations of clinical research. New Haven: Yale University Press; 1988.

23. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.

24. Committee for Human Medicinal Products. Guideline for Good Clinical Practice (ICH). London: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH); 2016.

25. The European Parliament, The Council of the European Union. Regulation on clinical trials on medicinal products for human use. 2014. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2014_536/reg_2014_536_en.pdf (Accessed 15 Apr 2020).

26. Sulmsay DP, Snyder L. Substituted interests and best judgments: an integrated model of surrogate decision making. JAMA. 2010;304(17):1946–7. https://doi.org/10.1001/jama.2010.1595.

27. Ryan DJ, O’Regan NA, Coacim RÖ, et al. Delirium in an adult acute hospital population: predictors, prevalence and detection. BMJ Open. 2013;3(1): e001772. https://doi.org/10.1136/bmjopen-2012-001772.

28. de la Cruz M, Fan L, Yennu S, Tanco K, Shin SH, Wu L, et al. The frequency of missed delirium in patients referred to palliative care in a comprehensive cancer center. Support Care Cancer. 2015;23(8):2427–33. https://doi.org/10.1007/s00520-015-2610-3.

29. Marcantonio ER. Delirium in Hospitalized Older Adults. N Engl J Med. 2017;377(15):1456–66. https://doi.org/10.1056/NEJMp1605501.

30. Pérez-Ros P, Martínez-Atun FM. Delirium assessment in emergency departments: A literature review. Diseases. 2019;17:14.

31. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113(2):941–8. https://doi.org/10.1067/mim.1990.10034819-113-12-941.

32. Wei LA, Fearing MA, Sternberg EJ, Inouye SK. The confusion assessment method: a systematic review of current usage. J Am Geriatr Soc. 2008;56(5):823–30. https://doi.org/10.1111/j.1532-5415.2008.01674.x.

33. Wong CL, Holroyd-Leduc J, Simel DL, Straus SE. Does this patient have dementia? Dtsch Arztebl Int. 2018;115(44):733–7. https://doi.org/10.1001/jama.2010.1595.

34. Lewis M, McMurray JJV, Adamopoulos S, Anand SS, Atar D, Bassand JP, et al. ESC guidelines for the diagnosis and management of acute heart failure: the Task Force for the diagnosis and management of acute heart failure of the European Society of Cardiology. Eur Heart J. 2016;37:2149–95. https://doi.org/10.1093/eurheartj/ehw310.

35. Okonkwo O, Griffith HR, Belue K, Landrigan PJ, Saigal CS, Smedira NG, et al. Recent trends in the incidence of stroke in the United States. JAMA. 2019;322(18):1785–96. https://doi.org/10.1001/jama.2019.9119.

36. Appelbaum PS, Grisso T. MacArthur competence assessment tool for clinical research (MacCAT-CR). Sarasota: Professional Resource Press; 2001.

37. Appelbaum PS, Grisso T, Rappaport LM. MacArthur competence assessment tool for children (MacCAT-C). Cincinnati: Developmental and Behavioral Pediatrics; 2006.

38. Appelbaum PS, Appelbaum JR, Grisso T. MacArthur competence assessment tool for legal decision-making (MacCAT-LD). New York: Cambridge University Press; 2011.

39. Appelbaum JR, Grisso T. MacArthur competence examination for clinical research (MacCAT-CR). Sarasota: Professional Resource Press; 2011.

40. Gilbert T, Bosquet A, Thomas-Antérion C, Bonnefoy M, Le Saux O. Assessing capacity to consent for research in cognitively impaired older patients. Clin Interv Aging. 2017;12:1553–63. https://doi.org/10.2147/CIA.S141905.

41. Mays NL, Pope C. Qualitative research: A guide for nurses and others. London: Springer; 2000.

42. Sacco et al. Philosophy, Ethics, and Humanities in Medicine (2021) 16:3. https://doi.org/10.1177/1471301207075625.

43. Zhang MH, Haq ZU, Braithwaite EM, Simon NC, Raz KM. A randomized, controlled trial of video supplementation on the cataract surgery informed consent process. Graefes Arch Clin Exp Ophthalmol. 2019;257:179–28.

44. Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, et al. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry. 2007;64(8):966–74. https://doi.org/10.1001/archpsyc.64.8.966.

45. Duron E, Boulay M, Vidal JS, Blin JE. Capacity to consent to biomedical research’s evaluation among older cognitively impaired patients. A study to validate the university of California brief assessment of capacity to consent questionnaire in French among older cognitively impaired patients. J Nutr Health Aging. 2013;17:5.

46. Mayer RE. Multimedia Learning. 2nd ed: Cambridge University Press; 2009.

47. Dwjing J. Participatory research: a method for process consent with persons who have dementia. Dementia. 2007;6(1):11–25. https://doi.org/10.1177/1471301207075625.

48. Zhang MH, Haq ZU, Braithwaite EM, Simon NC, Raz KM. A randomized, controlled trial of video supplementation on the cataract surgery informed consent process. Graefes Arch Clin Exp Ophthalmol. 2019;257:179–28.

49. Schauer C, Floyd T, Chin J, Vandal A, Lampen-Smith A. Video or verbal? A randomised trial of the informed consent process prior to endoscopy. New Zealand Med J. 2019;132(1489):57–68.

50. Pallett AC, Nguyen BT, Klein NM, Phippen N, Miller CR, Barnett JC. A randomized controlled trial to determine whether a video presentation improves informed consent for hystectomy: Am J Obstet Gynecol. 2018;219:277.e1–7.

51. Lattuca B, Barber-Charnoux N, Alos B, Sfasi A, Mulliez A, Miton N, et al. Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: a randomized trial. Ann Heart. 2018;20067–74. https://doi.org/10.1093/ahj/haj2018.03.006.

52. Dhar J, Kanjago Y, Nambozo MR, Odeke NM, Abeso J, Dusabe-Richards J, et al. Optimising informed consent for participants in a randomised controlled trial in rural Uganda: a comparative prospective cohort mixed-methods study. Trials. 2018;19(1):699. https://doi.org/10.1186/s13063-018-3030-8.

53. Jeste DV, Palmer BW, Golshan S, Eyler LT, Dunn LB, Meeks T, et al. Multimedia consent for research in people with schizophrenia and Normal persons who have dementia. Dementia. 2007;6(1):11–25. https://doi.org/10.1177/1471301207075625.

54. Synnot A, Ryan R, Prictor M, Fetherstonhaugh D, Parker B. Audio-visual presentation of information for informed consent for participation in clinical trials. Cochrane Database Syst Rev. 2014;2014(5):CD003717. https://doi.org/10.1002/14651858.CD003717.pub4.

55. Abujarad F, Alfano S, Bright TJ, Kannoth S, Grant N, Gueble M, et al. Building an informed consent tool starting with the patient: the patient-centered virtual multimedia interactive informed consent (VI) CAMMA Annu Symp Proc. 2017;2017:374–83.

56. Novitzky P, Smeaton AF, Chen C, et al. A review of contemporary work on the ethics of ambient assisted living Technologies for People with dementia. Sci Ethic. 2014;21:707–65.

57. Årnason V, Li H, Cong Y. Informed consent. In: The SAGE Handbook of Ethics, Law and Health. New York: Sage; 2015.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions